LHLabcorp

Health care · Medical Labs · NYSE

Labcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. 10-K, Item 1

Headquarters: Burlington, NC
CEO: Adam H. Schechter
Next results: around Feb 16, 2027

Compare with peers → Embed

RevenueFY2016–25 $14.0B+7.2% FY2024: $13.0B 10-K FY2025 · XBRL Net incomeFY2016–25 $876.5M+17.5% FY2024: $746.0M 10-K FY2025 · XBRL Free cash flowFY2016–25 $1.2B+10.0% FY2024: $1.1B 10-K FY2025 · XBRL Operating marginFY2016–25 9.9%+1.6 pts 13.3% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 24, 2026 against Feb 25, 2025

Area	What changed	Source
Risk factors	26 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Accounting checks	11 other checks clear	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	4 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 24, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-25. Quoted as filed.

Natural disasters (e.g., severe weather, fires, and earthquakes), geopolitical events (e.g., terrorism, war, and political instability), public health crises, criminal activity, supply chain disruptions, and other events beyond the Company’s control could negatively affect the Company’s operations. These disruptions may temporarily…
10-K, Item 1A

All 26 new paragraphs →

Accounting checks

latest 10-K

11 of 11 clear 0 worth a look. Checks, not verdicts.

✓
Receivables +8.2% vs revenue +7.2% (+1.0 pts)
✓
Cash from operations $1.6B vs net income $876.5M (FY ending 2025-12-31)
✓
Inventory +8.4% vs revenue +7.2% (+1.2 pts)
✓
Same auditor in both 10-Ks: Deloitte & Touche LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
The same matters as last year: Valuation of Labcorp Diagnostics (Dx) Segment Net Accounts Receivable; F-2
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nov 4, 20268-K Regulation FD disclosure 8-K item 7.01
Oct 30, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
Oct 28, 20268-K Quarterly results 8-K item 2.02
Oct 21, 20268-K Regulation FD disclosure 8-K item 7.01

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on LH in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/LH/export.csv") into a cell.